- ProMIS Neurosciences (PMN) has announced a proposed public offering of units for gross proceeds of up to US$15,000,000
- Each unit consists of one common share and one-quarter of one common share purchase warrant
- The company expects to close the offering on or about August 24, 2021
- ProMIS intends to use the proceeds to advance its lead Alzheimer’s therapy PMN310
- ProMIS is a development-stage biotechnology company
- ProMIS Neurosciences Inc. (PMN) closed at C$0.215 per share
ProMIS Neurosciences (PMN) has announced a proposed public offering of units for gross proceeds of up to US$15,000,000.
Each unit consists of one common share and one-quarter of one common share purchase warrant. Each whole warrant will entitle the holder to purchase one common share at any time up to 60 months following the closing of the offering.
The offering is expected to be conducted by way of a private placement.
ProMIS intends to enter into an agency agreement with Leede Jones Gable Inc. and other agents to be added to the syndicate.
The company expects to close the offering on or about August 24, 2021.
The offering is subject to satisfaction of customary closing conditions, including the approval of the listing of the common shares and the warrant shares on the TSX.
ProMIS intends to use the proceeds to advance its lead Alzheimer’s therapy PMN310 to the filing of an Investigational New Drug application to enable a first clinical trial.
ProMIS is a development-stage biotechnology company focused on discovering and developing antibody therapeutics selectively targeting the development and progression of neurodegenerative diseases, in particular Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinson’s disease (PD).
ProMIS Neurosciences Inc. (PMN) closed at C$0.215 per share.
